BACKGROUND: Glioblastomas exhibit a high level of chemotherapeutic resistance, including to the antimitotic agents vincristine and taxol. During the mitotic agent-induced arrest, glioblastoma cells are able to perform damage-control and self-repair to continue proliferation. Monopolar spindle 1 (MPS1/TTK) is a checkpoint kinase and a gatekeeper of the mitotic arrest. METHODS: We used glioblastoma cells to determine the expression of MPS1 and to determine the effects of MPS1 inhibition on mitotic errors and cell viability in combination with vincristine and taxol. The effect of MPS1 inhibition was assessed in different orthotopic glioblastoma mouse models (n = 3-7 mice/group). MPS1 expression levels were examined in relation to patient survival. RESULTS: Using publicly available gene expression data, we determined that MPS1 overexpression corresponds positively with tumor grade and negatively with patient survival (two-sided t test, P < .001). Patients with high MPS1 expression (n = 203) had a median and mean survival of 487 and 913 days (95% confidence intervals [CI] = 751 to 1075), respectively, and a 2-year survival rate of 35%, whereas patients with intermediate MPS1 expression (n = 140) had a median and mean survival of 858 and 1183 days (95% CI = 1177 to 1189), respectively, and a 2-year survival rate of 56%. We demonstrate that MPS1 inhibition by RNAi results in sensitization to antimitotic agents. We developed a selective small-molecule inhibitor of MPS1, MPS1-IN-3, which caused mitotic aberrancies in glioblastoma cells and, in combination with vincristine, induced mitotic checkpoint override, increased aneuploidy, and augmented cell death. MPS1-IN-3 sensitizes glioblastoma cells to vincristine in orthotopic mouse models (two-sided log-rank test, P < .01), resulting in prolonged survival without toxicity. CONCLUSIONS: Our results collectively demonstrate that MPS1, a putative therapeutic target in glioblastoma, can be selectively inhibited by MPS1-IN-3 sensitizing glioblastoma cells to antimitotic drugs.
BACKGROUND:Glioblastomas exhibit a high level of chemotherapeutic resistance, including to the antimitotic agents vincristine and taxol. During the mitotic agent-induced arrest, glioblastoma cells are able to perform damage-control and self-repair to continue proliferation. Monopolar spindle 1 (MPS1/TTK) is a checkpoint kinase and a gatekeeper of the mitotic arrest. METHODS: We used glioblastoma cells to determine the expression of MPS1 and to determine the effects of MPS1 inhibition on mitotic errors and cell viability in combination with vincristine and taxol. The effect of MPS1 inhibition was assessed in different orthotopic glioblastomamouse models (n = 3-7 mice/group). MPS1 expression levels were examined in relation to patient survival. RESULTS: Using publicly available gene expression data, we determined that MPS1 overexpression corresponds positively with tumor grade and negatively with patient survival (two-sided t test, P < .001). Patients with high MPS1 expression (n = 203) had a median and mean survival of 487 and 913 days (95% confidence intervals [CI] = 751 to 1075), respectively, and a 2-year survival rate of 35%, whereas patients with intermediate MPS1 expression (n = 140) had a median and mean survival of 858 and 1183 days (95% CI = 1177 to 1189), respectively, and a 2-year survival rate of 56%. We demonstrate that MPS1 inhibition by RNAi results in sensitization to antimitotic agents. We developed a selective small-molecule inhibitor of MPS1, MPS1-IN-3, which caused mitotic aberrancies in glioblastoma cells and, in combination with vincristine, induced mitotic checkpoint override, increased aneuploidy, and augmented cell death. MPS1-IN-3 sensitizes glioblastoma cells to vincristine in orthotopic mouse models (two-sided log-rank test, P < .01), resulting in prolonged survival without toxicity. CONCLUSIONS: Our results collectively demonstrate that MPS1, a putative therapeutic target in glioblastoma, can be selectively inhibited by MPS1-IN-3 sensitizing glioblastoma cells to antimitotic drugs.
Authors: William A Freije; F Edmundo Castro-Vargas; Zixing Fang; Steve Horvath; Timothy Cloughesy; Linda M Liau; Paul S Mischel; Stanley F Nelson Journal: Cancer Res Date: 2004-09-15 Impact factor: 12.701
Authors: Loren Michel; Elena Diaz-Rodriguez; Gopeshwar Narayan; Eva Hernando; Vundavalli V V S Murty; Robert Benezra Journal: Proc Natl Acad Sci U S A Date: 2004-03-15 Impact factor: 11.205
Authors: Eric A Lee; Michael K Keutmann; Melissa L Dowling; Eleanor Harris; Gordon Chan; Gary D Kao Journal: Mol Cancer Ther Date: 2004-06 Impact factor: 6.261
Authors: Fei Chen; Eva P Szymanski; Kenneth N Olivier; Xinyue Liu; Hervé Tettelin; Steven M Holland; Priya Duggal Journal: Am J Respir Crit Care Med Date: 2017-12-15 Impact factor: 21.405
Authors: Ning Jin; Robert F Lera; Rachel E Yan; Fen Guo; Kim Oxendine; Vanessa L Horner; Yang Hu; Jun Wan; Ryan J Mattison; Beth A Weaver; Mark E Burkard Journal: Genes Chromosomes Cancer Date: 2020-07-18 Impact factor: 5.006
Authors: Jon E Hawkinson; Rondedrick Sinville; Deepti Mudaliar; Jagathpala Shetty; Timothy Ward; John C Herr; Gunda I Georg Journal: ChemMedChem Date: 2017-10-20 Impact factor: 3.466
Authors: Jacqueline M Mason; Xin Wei; Graham C Fletcher; Reza Kiarash; Richard Brokx; Richard Hodgson; Irina Beletskaya; Mark R Bray; Tak W Mak Journal: Proc Natl Acad Sci U S A Date: 2017-03-07 Impact factor: 11.205
Authors: Roger B Slee; Brenda R Grimes; Ruchi Bansal; Jesse Gore; Corinne Blackburn; Lyndsey Brown; Rachel Gasaway; Jaesik Jeong; Jose Victorino; Keith L March; Riccardo Colombo; Brittney-Shea Herbert; Murray Korc Journal: Mol Cancer Ther Date: 2013-11-26 Impact factor: 6.261
Authors: Balázs Győrffy; Giulia Bottai; Jacqueline Lehmann-Che; György Kéri; László Orfi; Takayuki Iwamoto; Christine Desmedt; Giampaolo Bianchini; Nicholas C Turner; Hugues de Thè; Fabrice André; Christos Sotiriou; Gabriel N Hortobagyi; Angelo Di Leo; Lajos Pusztai; Libero Santarpia Journal: Mol Oncol Date: 2014-01-05 Impact factor: 6.603